Evaluation of the palatabilities in 10 different famotidine orally disintegrating tablets by combination of disintegration device and taste sensor

Drug Development and Industrial Pharmacy

Volumn 41, Issue 8, 2015, Pages 1387-1392

  Yoshida, Miyako ^a   Hazekawa, Mai ^a   Haraguchi, Tamami ^a   Uchida, Takahiro ^a  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Disintegration device; Famotidine; Gustatory sensation test; Orally disintegrating tablets; Taste sensor

Indexed keywords

FAMOTIDINE; TABLET;

ADULT; ARTICLE; BITTER TASTE; DIFFERENTIAL THRESHOLD; EVALUATION STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MOUTH CAVITY; NORMAL HUMAN; PALATABILITY; SENSATION; SENSOR; TABLET; TABLET HARDNESS; TIME; ADOLESCENT; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; SOLUBILITY; TASTE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DRUG EVALUATION, PRECLINICAL; FAMOTIDINE; FEMALE; HUMANS; SOLUBILITY; TABLETS; TASTE; YOUNG ADULT;

EID: 84938307640     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.954583     Document Type: Article

References (29)

1. Bi Y, Sunada H, Yonezawa Y, et al. Preparation and evaluation of a compress tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull 1996;44:2121-7.
2. Masuda Y. The current and formulation design of fast oraldisintegrating tablets. Pharm Tech Jpn 2006;22:401-12.
3. Narazaki R, Harada T, Takami N, et al. A new method for disintegration studies of rapid disintegrating tablet. Chem Pharm Bull 2004;52:704-7.
4. Kashima A, Kobayashi T, Kobayashi M, et al. Evaluation of quality of orodispersible famotidine tablets. Jpn J Health Care Sci 2006;32: 511-16.
5. Hashimoto Y, Matsunaga C, Tokuyama E, et al. The quantitative prediction of bitterness-suppressing effect of sweeteners on the bitterness of famotidine by sweetness-responsive sensor. Chem Pharm Bull 2007;55:739-46.
6. European Pharmacopoeia 8. 0. Orodispersible tablets. France: European Directorade for the quality of medicine and healthcare, 2014:811.
7. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: orally disintegrating tablets. Silver Spring, MD: U. S. Department of Health and Human Services; 2008.
8. Harada T, Narazaki R, Nagira S, et al. Evaluation of the disintegration properties of commercial famotidine 20 mg orally disintegrating tablets using a simple new test and human sensory test. Chem Pharm Bull 2006;54:1072-5.
9. Kakutani R, Muro H, Makino T. Development of a new disintegration method for orally disintegrating tablets. Chem Pharm Bull 2010;58:885-90.
10. Tachiki H, Uchiyama H, Okuda Y, et al. Bitterness evaluation of famotidine orally disintegrating tablets using a taste sensor. Jpn J Med Pharm Sci 2005;54:321-7.
11. Hashimoto Y, Matsunaga C, Tokuyama E, et al. The quantitative prediction of bitterness-suppressing effect of sweeteners on the bitterness of famotidine by sweetness-responsive sensor. J Pharm Pharmacol 2002;54:1323-8.
12. Akiyoshi T, Tanaka N, Nakamura T, et al. Effects of quinine on the intracellular calcium level and membrane potential of PC12. J Pharm Pharmacol 2007;59:1521-6.
13. Yoshida M, Tokuyama E, Hazekawa M, Uchida T. Bitterness suppression of the Kampo medicine 'orengedokuto' using flavoured jellies. Chem Pharm Bull 2010;58:449-53.
14. Ito M, Yoshida M, Kobayashi Y, et al. Bitterness evaluation of H1-receptor antagonists using a taste sensor. Sens Mater 2011;23: 483-92.
15. Katsuragi Y, Mitsui Y, Umeda T, et al. Basic studies for the practical use of bitterness inhibitors: selective inhibition of bitterness by phospholipids. Pharm Res 1997;14:720-4.
16. Mizumoto T. Formulation design of a novel fast-disintegrating tablet. Int J Pharm 2005;306:83-90.
17. Sugimoto M, Matsubara K, Koida Y, Kobayashi M. The preparation of rapidly disintegrating tablets in the mouth. Pharm Dev Technol 2001;6:487-93.
18. Sugimoto M, Maejima T, Narisawa S, et al. Factors affecting the characteristics of rapidly disintegrating tablets in the mouth preparedby the crystalline transition of amorphous sucrose. Int J Pharm 2005; 296:64-72.
19. Sugimoto M, Narisawa S, Matsubara K, et al. Effect of formulated ingredients on rapidly disintegrating oral tablets prepared by crystalline transition method. Chem Pharm Bull 2006;54:175-80.
20. Sugimoto M, Narisawa S, Matsubara K, et al. Development of manufacturing method for rapidly disintegrating oral tablets using the crystalline transition of amorphous sucrose. Int J Pharm 2006; 320:71-8.
21. Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009;139:94-107.
22. Abdelbary A, Elshafeey AH, Zidan G. Comparative effects of different cellulosic-based directly compressed orodispersable tablets on oral bioavailability of famotidine. Carbohydrate Polymers 2009; 77:799-806.
23. Nakano Y, Maeda A, Uchida S, Namiki N. Preparation and evaluation of unpleasant taste-masked pioglytazone orally disintegrating tablets. Int J Pharm 2013;446:160-5.
24. Lou H, Liu M, Qu W, et al. Evaluation of chlorpheniramine maleate microparticles in orally disintegrating film and orally disintegrating tablet for pediatrics. Drug Dev Ind Pharm 2014;40:910-18.
25. Dehaene S. The neural basis of the Weber-Fecher law: A logarithmic mental number line. Trend Cogn Sci 2003;7:145-7.
26. Miyanaga Y, Inoue N, Ohnishi A, et al. Quantitative prediction of the bitterness suppression of elemental diets by various flavors using a taste sensor. Pharm Res 2003;20:1932-8.
27. Uchida T, Sugino Y, Hazekawa M, et al. Factors affecting the bitterness intensities of ten commercial formulations of ambroxol. Chem Pharm Bull 2012;60:949-54.
28. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm 2004;30: 429-48.
29. Choi du H, Kim NA, Nam TS, et al. Evaluation of taste-masking effects of pharmaceutical sweeteners with an electronic tongue system. Drug Dev Ind Pharm 2014;40:308-17.